Related Experiment Video

Updated: Jun 10, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented

Julen Oyarzabal1, Natasha Zarich, María Isabel Albarran

  • 1Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain. joyarzabal@cnio.es

Journal of Medicinal Chemistry
|August 21, 2010
PubMed

Insights

Researchers identified potential drug candidates by virtually screening millions of compounds to inhibit MNK1, a protein kinase involved in cancer. This study offers starting points for developing new cancer treatments targeting MNK1.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogenic translation factor eIF4E.
  • eIF4E phosphorylation at serine 209 is crucial for its oncogenic activity.
  • Targeting MNK1 presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To identify pharmacological inhibitors of MNK1 through virtual screening.
  • To validate MNK1 as a drug target for cancer therapy.
  • To discover starting points for medicinal chemistry optimization.

Main Methods:

  • Comprehensive virtual screening of a large compound database (18.8 million structures).
  • Assay of 1236 selected compounds against MNK1.
  • Hit characterization including IC50 determination and ligand efficiency calculation.

Main Results:

  • Identified 26 compounds with IC50 values below 10 μM, achieving a 2.10% hit rate.
  • The most potent compound exhibited an IC50 of 117 nM.
  • A significant portion of hits (73.1%) were fragments, with high ligand efficiency (0.32-0.52 kcal/mol/heavy atom).

Conclusions:

  • Virtual screening effectively identified potent MNK1 inhibitors.
  • The identified compounds and scaffolds represent promising starting points for developing novel cancer therapeutics.
  • Pharmacological inhibition of MNK1 warrants further investigation for cancer treatment.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...